@article {1726,
	title = {Recent advances in the therapeutic perspectives of Nutlin-3.},
	journal = {Curr Pharm Des},
	volume = {17},
	year = {2011},
	month = {2011},
	pages = {569-77},
	abstract = {<p>Nutlin-3 is a small molecule inhibitor of the MDM2/p53 interaction, which leads to the non-genotoxic p53 stabilization, activation of cell cycle arrest and apoptosis pathways. A series of recent studies have strengthened the concept that selective, non-genotoxic p53 activation by Nutlin-3 might represent an alternative to the current cytotoxic chemotherapy, in particular for pediatric tumors and for hematological malignancies, which retain a high percentage of p53(wild-type) status at diagnosis. Like most other drugs employed in cancer therapy, it will be unlikely that Nutlin-3 will be used as a monotherapy. In this respect, Nutlin-3 shows a synergistic cytotoxic effect when used in combination with innovative drugs, such as TRAIL or bortozemib. Although Nutlin-3 is currently in phase I clinical trial for the treatment of retinoblastoma, its effects on normal tissues and cell types remain largely to be determined and will require further investigation in the future years.</p>},
	keywords = {Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Drug Synergism, Genes, p53, Humans, Imidazoles, Neoplasms, Piperazines, Proto-Oncogene Proteins c-mdm2, Tumor Suppressor Protein p53},
	issn = {1873-4286},
	author = {Secchiero, Paola and Bosco, Raffaella and Celeghini, Claudio and Zauli, Giorgio}
}
